Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
32 participants
INTERVENTIONAL
2015-09-30
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives: This study is designed to assess the effects of an optimized regimen of UFH on the hemostatic environment downstream from the vascular clamp in major vascular surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization
NCT04725201
Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin
NCT02970032
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
NCT02334007
Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients
NCT02707263
Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis
NCT00450645
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Unfractionated heparin is commonly used during arterial vascular surgery to prevent thrombosis and accumulation of thrombi at the surgical site. UFH is administered before clamping and blood flow interruption. However, the best heparin regimen to achieve optimal anticoagulation for peripheral revascularization remains unknown, with current recommendations based on data from the coronary literature and guidelines. Few studies have assessed the effect of vascular clamping and blood flow interruption on the anticoagulation in the distal vascular bed.
Perioperative monitoring of coagulation is important to diagnose potential causes of hemorrhage and guide hemostatic therapies. Routine laboratory-based coagulation tests such as prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (aPTT) and platelet count are used to assess the patient's coagulation status. However, the value of these tests has been questioned in the acute perioperative setting for the following reasons: substantial delays between blood sampling and results, tests performed on plasma rather than whole blood and lack of information on platelet function.
The activated clotting time (ACT) is used to monitor anticoagulation and, indirectly, concentrations of UFH. The ACT is measured on whole blood in cuvettes containing high concentrations of activators, typically celite or kaolin. Modern methods are completely automated. ACT measurement with point-of-care devices is used during procedures requiring anticoagulation, such as cardiopulmonary bypass, interventional cardiology and hemodialysis. In vascular surgery, the target ACT is not clearly defined and therefore not systematically monitored.
Thromboelastography (TEG) is a bedside coagulation test that enables evaluation of all components of hemostasis. An advantage of TEG over conventional tests of hemostasis is that it is performed on whole blood, taking into consideration the role of interacting blood elements. The TEG can also be adapted to different clinical situations. Activators such as tissue factor, celite and thrombin can be added to whole blood to accelerate the analysis. TEG cups coated with heparinase can also be used to degrade heparin without affecting other coagulation parameters.
Ankle-brachial (ABI) and toe-brachial (TBI) indexes are currently used to evaluate patients with peripheral arterial disease. These non-invasive tests provide information about peripheral blood flow. The ankle-brachial index is the ratio of the systolic blood pressure at the ankle to that measured at the brachial artery. The diagnostic limits of the ABI have been confirmed in several large-scale studies. Conditions associated with medial calcifications, such as diabetes, chronic kidney disease or advanced age, can lead to false results due to vessel stiffness. The toe vessels are less susceptible to vessel stiffness, which makes the TBI useful.
Methods:
Monitoring and postoperative analgesia will be left to the discretion of the attending anesthesiologist. Surgery will be performed under general or regional anesthesia. For safety reasons, patients under regional anesthesia will automatically be assigned to receive a fixed dose of heparin.
UFH will be administered 2 minutes prior to vascular clamping according to randomization. Blood samples will be collected at the following time points for ACT and TEG analysis: following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room. Heparin will be neutralized with protamine if needed.
Intraoperative blood losses will be recorded. Administration of crystalloids, colloids and blood products during surgery will be noted. Blood samples to assess cardiac troponin levels will be collected in the recovery room and on the day following surgery. Ankle-brachial and toe-brachial indexes will be measured preoperatively and postoperatively in the recovery room. The occurrence of cardiovascular complications will be noted during the hospital stay. The incidence of vascular re-interventions will be noted 30 days following surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fixed heparin dose (general anesthesia)
Study subjects will be randomized to receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
ACT
Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
TEG
Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
Ankle-brachial index
Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
Toe-brachial index
Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
Heparin
Heparin doses will be administered according to the assigned group.
Weight-adjusted doses of heparin
Study subjects will be randomized to receive 100 units of heparin per kilogram administered intravenously 2 minutes before vascular clamping and blood flow interruption. Subsequent doses of heparin will be administered to maintain the ACT between 300 and 350 seconds at all times during vascular clamping. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
ACT
Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
TEG
Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
Ankle-brachial index
Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
Toe-brachial index
Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
Heparin
Heparin doses will be administered according to the assigned group.
Fixed heparin dose (regional anesthesia)
For safety reasons, study subjects under regional anesthesia will automatically be assigned to this group and will receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG.
ACT
Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
TEG
Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
Heparin
Heparin doses will be administered according to the assigned group.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACT
Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
TEG
Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
Ankle-brachial index
Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
Toe-brachial index
Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
Heparin
Heparin doses will be administered according to the assigned group.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Society of Anesthesiologists (ASA) physical status l-lll inclusive
Exclusion Criteria
* Contraindication to heparin or protamine
* Known or suspected coagulopathy
* Current anticoagulation or residual effect of anticoagulants, antiplatelet agents, except aspirin
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre hospitalier de l'Université de Montréal (CHUM)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hardy Jean-François, MD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
Centre hospitalier de l'Université de Montréal (CHUM)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier de l'Université de Montréal (CHUM-Hôtel-Dieu)
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Roy M, Todorov A, Ruel M, Elkouri S, Hardy JF. Anticoagulation Obtained below the Arterial Clamp Using a Single Fixed Bolus of Heparin in Vascular Surgery: A Pilot Study. Ann Vasc Surg. 2018 Jul;50:242-248. doi: 10.1016/j.avsg.2017.11.060. Epub 2018 Feb 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15.077
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.